Navigation Links
Clinical Study Shows Regenecare Relieves Pain and Itching of Skin,Rashes Caused by Widely Used Cancer Drugs

IRVING, Texas--(BUSINESS WIRE)--Jul 11, 2007 - The Journal of the American Society of Clinical Oncology has published the early results of a clinical study conducted by Dr. Siu-Fun Wong, and her colleagues, which concluded that the topical gel, Regenecare(R), caused a statistically significant reduction in the pain and itching of a rash that results from the use of anti-cancer drugs known as EGFR inhibitors. This ongoing supportive care trial is listed on the National Cancer Institute Clinical Trials website (www.cancer.gov).

Paul Miller, President of MPM Medical, stated, "EGFR inhibitors form a group of drugs, sold by several pharmaceutical companies, which are effective in the treatment of cancer. However, after a few weeks of use, an acne-like rash often appears on the face, neck, back, hands, and/or legs resulting in severe pain and itching for the patient. We know of no other evidence-based topical applications reported in the scientific literature shown to help manage rash symptoms caused by EGFR drugs."

Regenecare(R) is a proprietary product of MPM Medical, Inc., a wholly owned subsidiary of RBC Life Sciences, Inc. (OTCBB:RBCL).

MPM Medical develops and markets a line of prescription and nonprescription products for wound management, through medical-surgical dealers, to nursing homes, hospitals, and cancer clinics.

The statements above, other than statements of historical facts, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

Contact

RBC Life Sciences, Inc.
Steve Brown, CFO, 972-893 4000
steveb@rbcls.com
www.mpmmedicalinc.com


'"/>




Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
3. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2019)... (PRWEB) , ... February 20, 2019 , ... John ... College Courses: Important Information That Is Nearly Never Covered in a University or College ... of his book’s 36 chapters is not covered in undergraduate courses of a major ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... for Job Syndrome by providing the scientific community with additional opportunities to further ... Fischer as Chief Scientific Officer of the Foundation’s Scientific Advisory Board and the ...
(Date:2/19/2019)... FL (PRWEB) , ... February 19, 2019 , ... Clearwater ... been told that they do not have the proper amount of bone to support ... bone grafting to improve the strength of the jaw bone. , Gum disease ...
Breaking Medicine Technology:
(Date:2/19/2019)... ST. LOUIS (PRWEB) , ... February 19, 2019 ... ... critical health system needs to improve care outcomes and patient experiences. Through ... target strategic journeys and audiences in key areas: , 1. Access Manager ...
(Date:2/19/2019)... ... February 19, 2019 , ... Crabapple Dental ... entire family with modern, state-of-the-art dental treatments in a comfortable environment. Dr. Sarah ... Dr. Roberts is known for providing advanced services in cosmetic and restorative dentistry, ...
(Date:2/19/2019)... ... February 19, 2019 , ... Reproductive Biology Associates ... States and a part of the Prelude Fertility (Prelude) network, announces ... Atlanta Hospital. , The only reproductive endocrinology practice on the Piedmont Atlanta hospital ...
(Date:2/19/2019)... ... 2019 , ... AdventHealth Connerton is the first specialty acute ... to maximize infection control for patients and their families. The patented, new technology ... difficile, which can be transmitted from the bottoms of shoes to patients, visitors ...
(Date:2/19/2019)... ... 2019 , ... Diploid , leading AI-based software provider for rare disease ... entered into a partnership to improve genome interpretation for rare disease diagnostics. , With ... diagnostics. Moon allows its users to go from VCF to causal variant in just ...
Breaking Medicine News(10 mins):